Prefer Glenmark Pharma: Tushar Mahajan

Tushar Mahajan - head of listed futures & options for India at Nomura Financial Advisory told CNBC-TV18, "In Glenmark Pharma surprisingly we have seen reasonable amount of open interest build up. The last 2-3 series has also seen very interestingly, it is one of those stocks which has had a good cost of carry as well."

"We like the stock, so you trade with the long bias and there could be more legs to go in for Glenmark," he added.

At 11:52 hrs Glenmark Pharma was quoting at Rs 926, up Rs 8.65, or 0.94 percent. It has touched a 52-week high of Rs 940.